Search Results
Sep 01, 2026, 07:30 ET Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
colorectal cancer. Paxalisib's approach in this setting represents a potential first-in-class strategy, as, to the Company's knowledge, no other PI3K/mTOR inhibitor has previously demonstrated meaningful activity in pMMR colorectal cancer.The Company plans to launch a five-arm Phase 2 clinical trial
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:15 ET Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
paxalisib is differentiated in targeting the PI3K/mTOR–epigenetic resistance axis and importantly, this is not a class effect," said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics. "Paxalisib's unique attributes are uncovering a broader role for PI3K/mTOR beyond conventional cytoplasmic signalling,
More news about: Kazia Therapeutics Limited
Aug 31, 2026, 17:58 ET Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over
More news about: Kazia Therapeutics Limited
Aug 28, 2026, 07:30 ET Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:09 ET Kazia Therapeutics Limited Announces Proposed Public Offering
development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
no paxalisib-related serious adverse events and no grade 3 or higher hyperglycemia, stomatitis or mucositis, toxicities commonly associated with PI3K/mTOR pathway inhibition.
More news about: Kazia Therapeutics Limited
Aug 25, 2026, 09:00 ET Agency Skin Announces Breakthrough Approach to Skin Longevity With New Personalized, Patent-Pending Treatments
patent-pending formula combines rapamycin and resveratrol, designed to target inflammaging while supporting firmer skin and improved elasticity. Rapamycin calms mTOR — a signaling protein that becomes overactive with age — to reduce inflammation and help cells repair themselves more efficiently.Cell RepairRx is
More news about: Agency Skin
Jul 14, 2026, 09:00 ET Fatty15 Wins Best Cellular Health Supplement Brand 2026 -- USA
including support for metabolic health, liver health, immune balance, red blood cell health, and cognitive health.* C15:0 also activates AMPK and inhibits mTOR, two of the most studied longevity-regulating pathways in the body, and repairs mitochondrial function, the cellular engines that decline with age.The
More news about: Seraphina Therapeutics
Jul 06, 2026, 10:31 ET Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight
vision impairment.Santen/ActualEyes' STN1010904 (sirolimus; AE-001) is an ophthalmic suspension intended for the treatment of FECD. As an mTOR inhibitor, the sirolimus-based eye drop is designed to prevent the formation of collagenous deposits (guttae) on the corneal endothelial surface and
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
and the reliance on combination therapy with MEK inhibitors.Kazia Therapeutics' Paxalisib is an investigational inhibitor of the PI3K/mTOR signaling pathway developed to cross the blood–brain barrier and inhibit abnormal molecular pathways associated with glioblastoma progression. Kazia
More news about: DelveInsight Business Research, LLP
Jun 23, 2026, 08:00 ET Rapalogix Health Raises $20 Million in Series A Financing to Redefine the Future of Longevity-Based Skin Health
today's most debilitating chronic diseases, with programs targeting critical metabolic sensing functions that decline with age, including AMPK and mTOR. To learn more, visit www.CambrianBio.com and follow us on
More news about: Rapalogix Health, Inc.
Jun 17, 2026, 08:00 ET Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress
In patients with signs and symptoms of TMA, consider ENVARSUS XR as a risk factor. Concurrent use of ENVARSUS XR and mammalian target of rapamycin (mTOR) inhibitors may contribute to the risk of TMA.ADVERSE REACTIONSDe Novo kidney transplant patients: Most common adverse reactions
More news about: Veloxis Pharmaceuticals
Jun 10, 2026, 10:01 ET Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight
deficiency disorder (CDD), and tuberous sclerosis complex (TSC). Among these, everolimus exemplifies a precision medicine approach by targeting the mTOR signaling pathway in TSC, highlighting the industry's growing emphasis on mechanism-based therapies in DEE.At the same time, fenfluramine is
More news about: DelveInsight Business Research, LLP
Jun 02, 2026, 07:30 ET Kazia Therapeutics Appoints James Levine as Chief Financial Officer
development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of 10
More news about: Kazia Therapeutics Limited
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
轉移性乳癌中觀察到的不同抗藥性機制，並且在不論 ESR1 突變狀態如何的情況下，提升患者治療成果。 研究包含六種治療方案，分別評估埃拉司群與 CDK4/6 抑制劑（帕博西尼 (palbociclib)、阿貝馬西利 (abemaciclib) 及瑞博西利 (ribociclib)），以及 PI3K/AKT/mTOR 訊號傳導途徑抑制劑（依維莫司 (everolimus)、阿培利西 (alpelisib) 和卡帕塞替尼 (capivasertib)）聯合治療的療效。2026 年美國臨床腫瘤學會週年大會上公佈的 ELEVATE 研究結果（摘要 1098）[1] 中，包括來自埃拉司群
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
terapeutici che valutano elacestrant in combinazione con inibitori di CDK4/6 (palbociclib, abemaciclib e ribociclib) e con inibitori della via PI3K/AKT/mTOR (everolimus, alpelisib e capivasertib).I risultati dello studio ELEVATE presentati all'ASCO 2026 (abstract 1098) [1] includono dati
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
tratamento que avaliam o elacestranto em combinação com inibidores de CDK4/6 (palbociclibe, abemaciclibe e ribociclibe) e com inibidores da via PI3K/AKT/mTOR (everolimo, alpelisibe e capivasertibe).Resultados do estudo ELEVATE apresentados na ASCO 2026 (resumo 1098) [1] incluem dados de
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
tratamiento que evalúan el elacestrant combinado con inhibidores de CDK4/6 (palbociclib, abemaciclib y ribociclib) y con inhibidores de la vía PI3K/AKT/mTOR (everolimus, alpelisib y capivasertib).Los resultados de ELEVATE que se presentaron en la ASCO 2026 (resumen 1098)[1] incluyen datos
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
Behandlungsschemata, in denen Elacestrant in Kombination mit CDK4/6-Inhibitoren (Palbociclib, Abemaciclib und Ribociclib) sowie mit Inhibitoren des PI3K/AKT/mTOR-Signalwegs (Everolimus, Alpelisib und Capivasertib) untersucht wird.Die auf der ASCO 2026 vorgestellten ELEVATE-Ergebnisse (Abstract 1098)[1]
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
évaluant l'élacestrant en association avec des inhibiteurs de CDK4/6 (palbociclib, abémaciclib et ribociclib) et avec des inhibiteurs de la voie PI3K/AKT/mTOR (évérolimus, alpelisib et capivasertib).Les résultats d'ELEVATE présentés à l'ASCO 2026 (résumé 1098)[1] comprennent les données d'innocuité
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
기전을 극복하고 ESR1 돌연변이 상태와 관계없이 환자 예후를 개선하기 위해 엘라세스트란트 병용 투여 옵션의 안전성과 유효성을 평가하도록 설계됐다. 이 시험은 엘라세스트란트를 CDK4/6 억제제(팔보시클립, 아베마시클립 및 리보시클립), PI3K/AKT/mTOR 경로 억제제(에베로리무스, 알펠리십 및 카피바서팁)와 각각 병용 평가하는 6개 치료 요법으로 구성돼 있다.ASCO 2026에서 보고되는 ELEVATE 결과(초록 1098)[1]에는 제1b상 엘라세스트란트(258~345mg)와 카피바서팁(320~400mg)
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 05:23 ET Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib
tratamiento que evalúan elacestrant en combinación con inhibidores de CDK4/6 (palbociclib, abemaciclib y ribociclib) y con inhibidores de la vía PI3K/AKT/mTOR (everolimus, alpelisib y capivasertib).Los resultados de ELEVATE presentados en ASCO 2026 (resumen 1098)[1] incluyen datos de seguridad y eficacia
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 12:46 ET Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
regimens evaluating elacestrant in combination with CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib) and with inhibitors of the PI3K/AKT/mTOR pathway (everolimus, alpelisib and capivasertib).ELEVATE results reported at ASCO 2026 (abstract 1098)[1] include safety and preliminary
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 07:30 ET Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research ("AACR"), demonstrating that dual PI3K/mTOR inhibition with paxalisib altered tumor cell state and immune signaling in preclinical TNBC models. TNBC accounts for approximately 15 to 20 percent
More news about: Kazia Therapeutics Limited
May 18, 2026, 07:54 ET Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer
inhibitors with up to 6 prior lines of therapy in the metastatic setting; approximately 40% and 36% of participants had received chemotherapy and PI3K/AKT/mTOR or other targeted therapies, respectively. Clinical Benefit Rates1 (CBRs) of 41.7% and 80% were observed in treatment-evaluable participants2
More news about: Biotheryx, Inc.